Pancreatic cancer 'time machine' exposes plot twist in cell growth and invasion

Pancreatic cancer 'time machine’ exposes plot twist in cell growth and invasion
Invasive cancer sprouts from an artificial pancreatic duct engineered by Purdue University researchers. The cell bodies are stained magenta and the nuclei are stained blue. Credit: Purdue University image/Stephanie Venis, Hye-ran Moon and Bumsoo Han

Pancreatic cancer has one of the worst survival rates among cancers. Patients can expect as low as a 9% chance to live for at least five years after being diagnosed.

Going back in time to observe how cells with key gene mutations interact and become invasive would help researchers better understand how the starts and identify it sooner.

A "" engineered by Purdue University researchers has revealed that the disease is even more unpredictable than previously thought: Cancer cells promote each other's invasiveness when they grow together.

The study, published in the journal Small, is just the beginning of a new discovery about how pancreatic cancer evolves. Since the paper's publication, the researchers also have found in cancer cell types originating from two drug-sensitive ones.

The time machine is a hollow tube of collagen that realistically mimics the microanatomy of a pancreatic duct. By injecting into microfluidic channels within the artificial duct, the researchers can use the system as a model for observing how pancreatic cancer behaves over time.

Typically, it takes 10-20 years for pancreatic cancer to develop in a patient. Even in an , the process is several months long. This pancreatic tumor model condenses cancer development to just two weeks.

"We can observe what happens over a long period of time. This helps us to see trends that we wouldn't normally see," said Bumsoo Han, a Purdue professor of mechanical engineering who builds models for studying how move in biological systems.

The tumor model speeds up time because researchers can load in from an animal model or patient without waiting for gene mutation to happen first. The life-like structure of the tumor model allows the researchers to reconstruct the mutation as it would happen in the body.

To go back in time, the researchers just rewind footage taken by imaging equipment from the side of the artificial duct.

For this study, a group led by Stephen Konieczny, a professor of biological sciences at Purdue, developed the pancreatic cell line in a mouse model. Han's team then loaded the cell line through the microfluidic channels of the artificial pancreatic duct. Once inside, the cell lines fill the duct and start growing.

What makes the tumor model so realistic is its shape.

"The curvature of the pancreatic duct affects the behavior of cells. We could culture these cancer cells on a , but because the dish is flat, we wouldn't see the same behavior," said Han, who is the program leader of the Purdue University Center for Cancer Research and has a courtesy appointment in biomedical engineering.

The researchers saw that after two different cancer cell types merged into the pancreatic tumor model device, these cells became more invasive and sprouted from the duct to form tumors.

Since cancer is technically a group of diseases, and pancreatic cancer involves four major driver mutations, Han's team plans to further explore how each of these mutations interacts with each other. The tumor model also can be used as a prescreening tool to discover new drug targets for better drugs, Han said.

More information: Michael J. Bradney et al. A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma, Small (2020). DOI: 10.1002/smll.201905500

Journal information: Small

Provided by Purdue University

Citation: Pancreatic cancer 'time machine' exposes plot twist in cell growth and invasion (2020, February 14) retrieved 15 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Bringing the 'sticky' back to pancreatic cancer


Feedback to editors